US · Healthcare · Biotechnology
EPS came in at -0.99 against a street estimate of -0.99 — a beat of 0.0%.
Analysts rate Axsome Therapeutics Inc a strong buy (21 buy, 1 hold, 0 sell out of 22) with an average price target of $283.63.
| Fund | Stake |
|---|---|
| BlackRock Inc | 5.93% |
| Vanguard Portfolio Management, LLC | 3.79% |
| Vanguard Capital Management, LLC | 3.75% |
| Amvescap Plc. | 3.19% |
| FMR Inc | 2.94% |
| Geode Capital Management, LLC | 1.85% |
| Assenagon Asset Management SA | 1.74% |
| Morgan Stanley - Brokerage Accounts | 1.54% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 AXSOME THERAPEUTICS, INC. – 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash position: $319.9 million as of June 30, 2026 (down slightly fr | 2026-08-10 |
| Results announced · Q3 2026 AXSOME THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total net product revenue: $218.4 million in Q2 2026, up 46% year-over-year | 2026-08-10 |
| Company announcement · Q3 2026 AXSOME THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Filing Date: July 15, 2026 • Company: Axsome Therapeutics, Inc. (Ticker: AXSM, Nasdaq) • | 2026-07-15 |
| Board / officer change · Q2 2026 AXSOME THERAPEUTICS, INC. — 8-K SUMMARY HEADLINE NUMBERS • Filing Date: June 9, 2026 (Event Date: June 5, 2026) • Company: Axsome Therapeutics, Inc. | 2026-06-09 |
| Shareholder vote results · Q2 2026 AXSOME THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 5, 2026 with 43,777,536 shares represented out of 51,439,952 tot | 2026-06-09 |
| Quarterly report · Q1 2026 AXSOME THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Product sales (Q1 2026): $189.4 million vs. $120.4 million in Q1 2025 – growth o | 2026-05-04 |
| Proxy statement · Q2 2026 AXSOME THERAPEUTICS, INC. — 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal One: Elect directors to serve as Class II d | 2026-04-24 |
| Annual report FY2025 AXSOME THERAPEUTICS, INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company trades on NASDAQ under ticker AXSM with 51,153,289 shares o | 2026-02-23 |
Readable in the app.
| Announcement | Date |
|---|---|
| FDA approval of AUVELITY for agitation associated with Alzheimer's disease Axsome Therapeutics announced FDA approval of AUVELITY (dextromethorphan HBr and bupropion HCl), a first-in-class medication for treating agitation associated with Alzheimer's disease dement | 2026-04-30 |
| Acquires exclusive global rights to selective PDE10A inhibitor balipodect Axsome Therapeutics acquired exclusive global rights to balipodect (TAK-063), a novel oral drug from Takeda, for treating schizophrenia and Tourette syndrome. Balipodect is a selective phosp | 2026-04-01 |
| Preliminary 4Q and full year 2025 net product revenue guidance provided Axsome Therapeutics reported strong preliminary 2025 revenue results, with full-year net product revenue of $638.5 million, representing 66% annual growth compared to 2024. The company's thr | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Axsome Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.